Efficacy and safety of second-line cabozantinib after immuno-oncology combination therapy for advanced renal cell carcinoma: Japanese multicenter retrospective study.
Sazuka T, Matsushita Y, Sato H, Osawa T, Hinata N, Hatakeyama S, Numakura K, Ueda K, Kimura T, Takahashi M, Tanaka H, Kawasaki Y, Kurahashi T, Kato T, Fujita K, Miyake M, Kojima T, Kitamura H, Miyake H, Ichikawa T.
Sazuka T, et al. Among authors: kojima t.
Sci Rep. 2023 Nov 23;13(1):20629. doi: 10.1038/s41598-023-48087-4.
Sci Rep. 2023.
PMID: 37996622
Free PMC article.